GlassScriptPhysician profile
Richard Blair Jackson
NPI 1164432357
$6,775.51
in general payments reported to CMS, 2019-2025
25 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,620 · 2020: $2,181 · 2021: $159 · 2022: $165 · 2023: $142 · 2024: $341 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,301.90 | 2019-2022 | |
| Medtronic, INC. | $180.26 | 2024 | Interstim |
| Tela Bio, INC. | $177.71 | 2019-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $161.96 | 2020-2022 | |
| Biom'Up Sa | $149.57 | 2019 | |
| Biom'Up France Sas | $136.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.52 | 2023-2024 | Gattex |
| Abbvie INC. | $62.33 | 2023-2025 | |
| Ethicon US, LLC | $57.69 | 2021-2025 | Vistaseal |
| Biotissue Holdings INC. | $51.21 | 2024-2025 | |
| Kerecis Limited | $48.70 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Integra Lifesciences Corporation | $46.44 | 2022 | |
| Shire North American Group INC | $39.93 | 2019 | |
| Acera Surgical, INC. | $38.37 | 2019-2024 | Restrata Wound Matrix |
| Davol INC. | $35.85 | 2024 | Phasix Mesh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $27.19 | 2019 | |
| Aroa Biosurgery Incorporated | $25.98 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $24.99 | 2025 | Exparel |
| Braintree Laboratories, INC. | $20.48 | 2019 | |
| Thd America, INC. | $19.86 | 2023 | |
| Becton, Dickinson and Company | $18.78 | 2022 | |
| Smith+Nephew, INC. | $18.57 | 2023 | Stravix Pl |
| Tetraphase Pharmaceuticals, INC. | $16.08 | 2019 | |
| Covidien LP | $15.67 | 2019 | |
| Acell, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.